Loading news...
Generic drugmakers face pricing pressure, but companies like TEVA, SDZNY and RDY are betting on complex generics and biosimilars to protect growth.
Stock rose 6.4% after the company bumped up its revenue guidance thanks to growth in its biosimilar product range.
Sandoz Group AG (SDZNY) Q4 2025 Earnings Call Transcript
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) and Sandoz Group AG Sponsored ADR (SDZNY).
Sandoz delivered steady revenue and EBITDA growth, with 2025 revenue projected near $11B and EBITDA margin guidance raised to 21-22%. SDZNY now trades at a relatively rich EV/EBITDA multiple of ~16 for 2025 and ~13 forward based on 2027 consensus estimates. While the business model and growth profile remain attractive, current valuation justifies only a "hold" rating after a 65% share price run-up.
Sandoz Group (OTCMKTS:SDZNY - Get Free Report) and Context Therapeutics (NASDAQ: CNTX - Get Free Report) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, profitability, earnings, dividends, institutional ownership, analyst recommendations and risk. Institutional and Insider Ownership 0.1% of Sandoz Group
Sandoz Group AG (SDZNY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Sandoz Group (OTCMKTS:SDZNY - Get Free Report) and Daiichi Sankyo (OTCMKTS:DSNKY - Get Free Report) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, institutional ownership, valuation, risk and earnings. Earnings and Valuation This table compares Sandoz
Sandoz Group AG Sponsored ADR (OTCMKTS:SDZNY - Get Free Report) rose 3.3% during trading on Friday. The company traded as high as $76.84 and last traded at $76.84. Approximately 2,413 shares traded hands during trading, a decline of 92% from the average daily volume of 29,782 shares. The stock had previously closed at $74.40.
Investors interested in Medical - Drugs stocks are likely familiar with Sandoz Group AG Sponsored ADR (SDZNY) and Stevanato Group (STVN). But which of these two stocks presents investors with the better value opportunity right now?
Generic drugmakers face U.S. pricing pressure, but TEVA, SDZNY and RDY gain momentum through complex generics and biosimilars.
All closing requirements satisfied following announcement of a non-binding term-sheet agreement in July and signing of contract in November Agreement includes approximately US$ 350 m in cash for Just - Evotec Biologics manufacturing site in Toulouse and upfront technology license fees to Evotec's continuous manufacturing platform In addition, Evotec eligible for license fees, and development revenues including success-based milestones adding up to more than US$ 300 m over the coming years,replacing existing contractual commitments Transaction covering royalties on a portfolio ofup to ten biosimilars in technical and early development targetingmore than US$ 90 bn of originator net sales Sale immediately earnings accretive, improving Evotec's short, mid and long-term revenue mix, profit margins, and capital efficiency HAMBURG, DE / ACCESS Newswire / December 8, 2025 / Evotec SE (Frankfurt Stock Exchange:EVT, SDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 566480; NASDAQ:EVO) today announced the closing of its previously reported sale of the Just - Evotec Biologics Toulouse site plus an indefinite technology license to Evotec's continuous manufacturing platform technology to Sandoz AG (SIX:SDZ / OTCQX:SDZNY), effective 05 December 2025. In total, potential payments may exceed US$ 650 m plus royalties on a portfolio of up to 10 biosimilar molecules, of which six have an originator net sales value of US$ 90 bn.
Sandoz Group AG Sponsored ADR (SDZNY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Investors looking for stocks in the Medical - Drugs sector might want to consider either Sandoz Group AG Sponsored ADR (SDZNY) or Stevanato Group (STVN). But which of these two companies is the best option for those looking for undervalued stocks?
We initiated seven new positions across themes including Japanese industrials, measured gold exposure and businesses with strong links to emerging markets. We initiated small positions in two companies with gold-linked cash flows: Franco-Nevada (FNV) and Agnico Eagle Mines (AEM). We exited four positions in the quarter, two REITs and two health care companies.
/PRNewswire/ -- EirGenix Inc. (TWSE: 6589) anunció el 12 de noviembre la firma de un segundo acuerdo global de licencia exclusiva con Sandoz AG
/PRNewswire/ -- EirGenix Inc.(TWSE: 6589) annoncé le 12 novembre la conclusion d'un deuxième accord mondial de licence exclusive avec le leader international
Generic drug giant Sandoz expects unbranded versions of Novo Nordisk's popular diabetes drug Ozempic to launch in Canada by the second quarter next year after a key patent expires, its CEO said on Wednesday.
/PRNewswire/ -- EirGenix Inc.(TWSE: 6589) today announced that it has entered into a second global exclusive licensing agreement with international biosimilar
TAIPEI , Nov. 12, 2025 /PRNewswire/ -- EirGenix Inc.(TWSE: 6589) today announced that it has entered into a second global exclusive licensing agreement with international biosimilar leader Sandoz AG (SIX:SDZ/OTCQX:SDZNY) for the commercialization of its independently developed breast cancer biosimilar, EG1206A (Pertuzumab Biosimilar to Roche Perjeta®), covering all territories except Taiwan, Mainland China, Macau, South Korea, Mongolia, Brunei, Cambodia, Indonesia, Laos, Myanmar, the Philippines, and Japan. The agreement further strengthens the two companies' collaborative development of the HER2 biosimilar product.